Furafylline is a methyl xanthine derivative with an expanded duration of action than that of theophylline. Furafylline acts as an inhibitor of CYP1A2 (cytochrome p450) and PDE (phosphodiesterase). Inhibition of CYP has the effect of slowing oxidative metabolism of xenobiotics, while inhibition of PDE prevents the hydrolysis of secondary messenger molecules, which in turn prolongs signal transduction and enhances its effects.
1. Boulenc, X., et al., 1992. Regulation of cytochrome P450IA1 gene expression in a human intestinal cell line, Caco-2. The Journal of pharmacology and experimental therapeutics. 263(3): 1471-8. PMID: 1469646
2. Sesardic, D., et al., 1990. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British journal of clinical pharmacology. 29(6): 651-63. PMID: 2378786
3. Segura, J., et al., 1986. Some pharmacokinetic characteristics of furafylline, a new 1,3,8-trisubstituted xanthine. The Journal of pharmacy and pharmacology. 38(8): 615-8. PMID: 2876080
See how others have used Furafylline. Click on the entry to view the PubMed entry .
PMID: # 26174047 Feng, R. et al. 2015. Scientific reports. 5: 12155.
PMID: # 25422175 Wang, W. et al. 2015. Chirality. 27: 170-6.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.